EEC 2026 Congress updates for Nordic

  1. Home
  2. You are here: EEC 2026 Congress updates for Nordic

European Epilepsy Congress (EEC) 2026, 5th – 9th September, Athens: topics, discussions and expert perspectives

These pages are dedicated to the ILAE Annual Congress 2026 in Athens, created specifically for the Nordic epilepsy community. Our goal is to provide Nordic healthcare professionals with relevant news, key highlights, and insights from this important event in epilepsy research and care.

At the ILAE Congress, experts discussed a range of topics currently shaping epilepsy care and research. These brief summaries of selected themes offer a quick understanding of what was discussed and the key takeaways from each topic.

1

Redefining Drug-Resistant Epilepsy

Does the current definition fully capture disease complexity?

Scientific debate focused on whether drug-resistant epilepsy should be viewed as a dynamic biological process rather than a binary outcome following treatment failure. Discussions considered the role of biomarkers, disease mechanisms, quality of life measures, and individualized treatment goals in future definitions.

Key takeaway
Future frameworks may move beyond seizure counts alone when assessing treatment success.
2

Network Perspectives on Epilepsy

Is epilepsy better understood as a disorder of brain networks rather than isolated seizure foci?

Advances in neuroimaging and electrophysiology continue to improve understanding of the large-scale brain networks involved in epilepsy. Experts discussed how network-based models may influence future approaches to diagnosis, surgical evaluation, neuromodulation, and treatment planning.

Key takeaway
Network science is reshaping our understanding of epileptic disorders.
3

Neuroinflammation and Epileptogenesis

Can targeting disease mechanisms alter the course of epilepsy?

Growing evidence links neuroinflammatory processes to seizure generation, disease progression, and cognitive outcomes. EEC 2026 sessions reviewed advances in understanding epileptogenesis and the potential role of inflammation-focused therapeutic strategies in modifying disease activity.

Key takeaway
Disease-modifying approaches are becoming an increasingly important area of epilepsy research.
4

Biomarkers in Epilepsy: From Research to Clinical Application

Are biomarkers ready to guide clinical decision-making?

Emerging research highlighted the potential of molecular, imaging, electrophysiological, and digital biomarkers to improve diagnosis, stratify patients, predict outcomes, and support treatment monitoring. While many approaches remain under investigation, the field is rapidly moving toward clinically actionable biomarkers.

Key takeaway
Biomarkers may become critical tools for personalized epilepsy management.
5

Genetic Diagnostics in Epilepsy: Moving Earlier in the Patient Journey

Should genetic testing be considered sooner and for more patients?

Presentations at EEC 2026 explored the expanding role of genetic testing across epilepsy syndromes. Evidence presented suggests that earlier identification of genetic aetiologies may improve diagnostic accuracy, inform treatment selection, support prognostic discussions, and facilitate access to precision medicine approaches.

Key takeaway
Genetic testing is increasingly shifting from a specialist tool to an integral component of epilepsy diagnostics.

Expert Perspectives from the Angelini satellite symposium

Angelini symposium

International epilepsy experts came together at the Angelini satellite symposium during the EEC 2026 to discuss current challenges and opportunities in epilepsy care. Explore the short video recordings below for highlights and key takeaways from the faculty. Each presentation is accompanied by selected speaker's slides shown in the symposium.

We are pleased to share talks from the Angelini Pharma Satellite Symposium at the 16th European Epilepsy Congress (EEC).At the heart of Angelini Pharma’s satellite symposium at EEC 2026 was a key question for modern epilepsy care: how can epilepsy care move beyond seizure reduction towards outcomes that are more ambitious and meaningful for patients?The international experts summarize their talks in these short videos – Click to hear their perspectives and insights drawn from clinical practice. Each video contains also selection of symposium slides.We will continue to add recordings, expert perspectives, and other congress materials to this page as new content becomes available, helping you stay up to date with the latest insights from the meeting.

PAUL BOON

Prof. Paul Boon (BEL) Beyond Seizure-Freedom: Brain Health and Holistic Outcomes in Epilepsy Care

This presentation explores the evolving treatment goals in epilepsy care, highlighting the importance of looking beyond seizure control alone. The session discusses how brain health, cognitive function, well-being, and quality of life can be integrated into a more holistic approach to patient management.

Paul Boon is Professor of Neurology at Ghent University and Lead Epileptologist at the Centre for Neurophysiological Monitoring, Ghent University Hospital, Belgium. He is a pioneer of epilepsy surgery and neuromodulation in Europe, past president of EAN and author of more than 800 scientific publications.

Key takeaways:

Brain Health is the destination. Seizure freedom is the path.
By striving for seizure freedom early and addressing the broader impacts of epilepsy, we can help protect Brain Health and empower patients to live fuller lives.1,2
Epilepsy control must extend beyond seizure count to whole Brain Health: Depression, anxiety, cognitive decline, and stigma are common, under-recognized, and bidirectionally linked to seizures, and they drive quality of life.3-6
Time is Brain: Earlier use of effective treatments provides the opportunity to preserve Brain Health across the patient’s lifetime.7-9

  1. Birbeck GL, Hays RD, Xinping C et al. Seizure Reduction and Quality of Life Improvements in People with Epilepsy. Epilepsia. 2002;43(5): 535-538.
  2. Boon P, Schmitz B, House P et al. Unlocking seizure freedom: A European Delphi panel study on the clinical, humanistic, and economic value of seizure control in epilepsy. Seizure. 2026;140:184-192.
  3. Baxendale SA, Wilson SJ, Baker GA et al. Ten things every neurologist needs to know about neuropsychological assessments and interventions in people with epilepsy. Eur J Neurol. 2020;27(1):215–220.
  4. Tombini M, Assenza G, Quintiliani L et al. Epilepsy and quality of life: what does really matter? Neurol Sci. 2021;42(9):3757-3765.
  5. Agrawal N, Bird JS, von Oertzen TJ et al. Depression correlates with quality of life in people with epilepsy independent of the measures used. Epilepsy Behav. 2016;62:246-250.
  6. Mula M, et al. Brodie MJ, de Toffol B et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia. 2022;63(2):316-334.
  7. Radhakrishnan A, Menon R, Thomas SJ et al. “Time is Brain”- How early should surgery be done in drug-resistant TLE? Acta Neurol Scand. 2018;138(6):531-540.
  8. Trinka E, Rainer LJ, Granbichler CA et al. Mortality, and life expectancy in Epilepsy and Status epilepticus—current trends and future aspects. Front Epidemiol. 2023;3:1081757.
  9. Thompson PJ, Duncan JS. Cognitive Decline in Severe Intractable Epilepsy. Epilepsia 2005;46:1780–1787.

MAT-DK-0103-P 16.11.2026

Denna webbsajt är avsedd för vårdpersonal i Sverige. Är du vårdpersonal?